http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114264757-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-72 |
| filingDate | 2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114264757-B |
| titleOfInvention | Biomarker combination of white matter lesions and its application |
| abstract | The present invention provides a combination of biomarkers for leukoencephalopathy and applications thereof, specifically, the biomarkers are ceramide (d18:0/24:1(15Z)), phosphatidylcholine (O-18:0/0 :0) and galactosylceramide (d18:0/16:0) in the preparation of detection reagents for diagnosing white matter lesions, through biomarkers ceramide (d18:0/24:1(15Z)), phospholipids Acylcholine (O‑18:0/0:0) and galactosylceramide (d18:0/16:0) combined with clinical indicators of body weight, height, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein, Any two of low-density lipoprotein, fasting blood glucose, homocysteine or glycosylated hemoglobin can be used to judge the risk of white matter lesions, and the test results are accurate and reliable. Combined with the detection model, early prevention and prevention of white matter lesions can be carried out. |
| priorityDate | 2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.